United States· US:0006-5083_173d4e50-376f-4db3-8650-5c8b80b4b8fa
KEYTRUDA QLEX
A medicinal product containing pembrolizumab; berahyaluronidase alfa, registered in United States by Merck Sharp & Dohme LLC.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- PEMBROLIZUMAB; BERAHYALURONIDASE ALFA
- Manufacturer
- Merck Sharp & Dohme LLC
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- August 9, 2026
Packs & prices · 1
- ndc110006-5083-01
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b926775e-bc54-421d-9ccf-31a5972ef544 GET /v1/drugs/b926775e-bc54-421d-9ccf-31a5972ef544?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "2000; 165",
"substance": "PEMBROLIZUMAB; BERAHYALURONIDASE ALFA",
"productndc": "0006-5083",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "U/mL; mg/mL",
"application_number": "BLA761467",
"marketing_category": "BLA"
}See everything about pembrolizumab; berahyaluronidase alfa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.